The use of aspirin in thromboembolic disease

J. C. DeLee, C. A. Rockwood

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Careful review of the literature and evaluation of the clinical trials reveals that the position of aspirin as an antithrombotic agent in orthopaedic patients is still not clear. Men who are more than 40 yr old, without a previous history of thromboembolic disease or venous surgery on the lower extremity, who are undergoing hip replacement, are the only group protected from pulmonary embolism by 600 milligrams of aspirin twice a day. These patients still have a relatively high (25%) incidence of deep venous thrombosis. There were, however, no patients treated with aspirin who had fatal pulmonary emboli in any of the studies reviewed. The decrease in pulmonary emboli in all patients, the absence of fatal emboli, and the low incidence of bleeding problems support the theory of the efficacy of aspirin.

Original languageEnglish (US)
Pages (from-to)149-152
Number of pages4
JournalJournal of Bone and Joint Surgery - Series A
Issue number1
StatePublished - Jan 1 1980

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine


Dive into the research topics of 'The use of aspirin in thromboembolic disease'. Together they form a unique fingerprint.

Cite this